5th ARDAT General Assembly Meeting
42 ARDAT members gathered in Barcelona, Spain, for the 5th ARDAT General Assembly Meeting, 28-29th April 2025, hosted by colleagues Asphalion. The two-day meeting began…
FDA Investigational New Drug (IND) approval for Spastic paraplegia type 47 gene therapy.
Work partly funded by ARDAT and originally developed by Professor Mimoun Azzouz and team at the University of Sheffield has been granted IND approval by…
Publishing in Nature Communications
Our ARDAT colleague Giuseppe Ronzitti (Genethon) and colleagues have published work investigating how AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS…
Society of Toxicology Meeting
Will Allen, US-based colleague of Dorota Kurek (Mimetas) presented a poster entitled: A high-throughput liver MPS capable of detecting small molecule and AAV-mediated hepatotoxicity…
Catarina Gomes successfully defends her PhD thesis (January 9th 2025)
Catarina Gomes successfully defended her PhD thesis (January 9th 2025) Catarina’s thesis, titled “Immunocompetent 3D Human Central Nervous System Models: A Novel Approach for Preclinical…
Summary of PPIE input to the ARDAT project 1/11/2023 – 31/10/2024
A group of eight individuals with lived experience was recruited to the project. They represent diversity in terms of condition type, whether they are affected…
Publishing in Frontiers in Bioengineering and Biotechnology
Our ARDAT colleagues have published in Frontiers in Bioengineering and Biotechnology. CRISPR-mediated gene activation (CRISPRa) encompasses a growing field of biotechnological approaches with exciting implications…
Dr Chris Mann, Scientific & Regulatory Director at Asphalion delivered lectures including discussions on the ARDAT project
Dr Chris Mann, Scientific & Regulatory Director at Asphalion delivered lectures including discussions on the Accelerating Research & Development for Advanced Therapies (ARDAT) project, as…
Dr Yvonne Katterle presented at the 17th EBF Open Symposium
Dr Yvonne Katterle, Head of Bioanalytics at Bayer presented an update on her ARDAT work on the “Strengths and weaknesses of different ligand binding assay…
Polyfunctional T cells and unique cytokine clusters imprint the anti rAAV2/rAAV9 vector immune response
We are pleased to report the publication of our recent paper in Frontiers in Immunology. The work provides insights into adaptive immunity with rAAV vector…
Dr Bernard Maillere presents at The Festival of Biologics
Dr Bernard Maillere, Research director in immunology at The French Alternative Energies and Atomic Energy Commission (CEA) gave a talk that included work completed in…
Luisa Hering and Felix Bubeck presenting their ARDAT work
Luisa Hering, PhD student at The University of Liverpool presenting her ARDAT work on AAV Vector-Specific Adaptive Immunogenicity at the 31st European Society of Gene…
PPIE event organised by ARDAT Coordinator, Professor Mimoun Azzouz (USFD).
The activity was included in the programme for the official launch of the Gene Therapy Innovation and Manufacturing Centre (GTIMC) at the University of Sheffield…
Pre-clinical development of AP4B1 gene replacement therapy for hereditary spastic paraplegia type 47
“We are pleased to report the publication of our recent paper at EMBO Molecular Medicine. The work describes the progress made in gene therapy approach…
PPIE Communication and Dissemination
A fantastic PPIE event and tour around the GTIMC facility at The University of Sheffield last week. Great to see the translational work of gene…
ARDAT’s WP4 Publishes Comprehensive Review on Immunosuppressive Protocols in AAV-Based Gene Therapy
We are proud to announce that our ARDAT colleagues from Work Package 4 have published a new paper in Molecular Therapy. The paper is a…
Clinical trial applications for investigational medicinal products that contain or consist of genetically modified organisms: industry experiences under the European Union Clinical Trial Regulation
Our colleagues have published the outcome of a survey of European Federation of Pharmaceutical Industries and Associations (EFPIA), The European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)…
ARDAT consortium celebrated a successful two-day general assembly meeting
In June 2024 the ARDAT consortium celebrated a successful two-day general assembly meeting (GAM) hosted by the University of Sheffield and all our colleagues for…
ARDAT General Assembly, Coimbra, Portugal 15/16 June 2023
The third face to face meeting for members of the ARDAT consortium was kindly hosted by the team from the Center for Neuroscience and Cell…
ARDAT General Assembly, Edinburgh UK 16/17 October 2022
Although the ARDAT Project has been running for almost 2 years, because of the restrictions placed upon travel and meeting throughout the COVID pandemic, all…
ARDAT Publishes its first Journal Article
Biodistribution, shedding and persistence of gene/cell therapies was identified by ARDAT WP5 partners as a key area for the focus of regulatory and harmonisation activities…
New Consortium aims to Standardize and Accelerate Development of Advanced Therapy Medicinal Products in €25.5 million project
Accelerating Research and Innovation for Advanced Therapies (ARDAT), a new, five-year European consortium supported by the Innovative Medicines Initiative (IMI), today announces its launch. The…